Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHOview Observational Study. Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.

NCT01703728 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.

NCT NCT01703728
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01703728 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHOview Observational Study. Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.
Lead sponsor
Ferring Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
November 30, 2012
Completion date
May 31, 2014
Enrollment
455 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian hyperstimulation syndrome (ohss)